Declines in motor function seen in SBMA despite long-term leuprorelin
Despite treatment with leuprorelin over three years, all spinal and bulbar muscular atrophy (SBMA) patients in a study in…
Articles by Lindsey Shapiro, PhD
Wait times for SMA specialists found shorter than for neurologists
Infants with suspected spinal muscular atrophy (SMA) who are directly referred to an SMA care center may experience shorter…
Two genes, NAIP and SMN2, may help determine SMA’s likely severity
Genetic alterations related to two genes, SMN2 and NAIP, could help to predict the severity of spinal muscular atrophy (SMA), according…
Long-term Spinraza found safe, effective across SMA spectrum
Long-term treatment with Spinraza (nusinersen) was associated with improved or stable motor function in patients across the spinal…
Grip strength may be better test of subtle upper limb changes in SMA
Measures of grip strength or mobility may help to capture subtle changes in upper limb function for children with…
Zolgensma helps boy with unstable SMA symptoms on Spinraza
Treatment with the gene therapy Zolgensma (onasemnogene abeparvovec) led to improved breathing and motor function for a young boy…
NfL protein levels may be helpful biomarker for SMA children: Study
Levels of the neurofilament light protein, known as NfL — which serves as an indicator of neurodegeneration — may be…
RESTORE data indicate real-world benefits of Zolgensma for SMA
Real-world treatment with Zolgensma (onasemnogene abeparvovec-xioi) was associated with motor and survival benefits for people with…
Proper nutrition can be lacking in children on Spinraza, study finds
Difficulties with adequate nutrition and feeding persist among children and adolescents with spinal muscular atrophy (SMA) types 2 and…
Neurodevelopmental issues emerging as patients live longer
About 43% of children with early-onset spinal muscular atrophy (SMA) were reported to have neurodevelopmental problems in a recent…